Navigation Links
CLAAD Petitions FDA To Reject Opioid Medications Without Safety Features
Date:6/11/2013

WASHINGTON, June 11, 2013 /PRNewswire-USNewswire/ -- The Center for Lawful Access and Abuse Deterrence (CLAAD) joined in signing a Citizen Petition filed today urging the Food and Drug Administration (FDA) to fully implement the Obama administration's policy supporting a market transition to safer opioid medications. The petition asks that the FDA reject applications for new opioid medications without added safety features.

Opioids are a class of synthetically derived chemicals often used to treat pain or addiction. Opioid analgesics were involved in over 16,000 overdose deaths in 2010 alone, according to the Centers for Disease Control.

The petition praises the FDA's recent steps to shift the market to safer medications, such as the April conclusion that the original OxyContin pill was removed from the market for safety reasons. Copies of the non-abuse-deterrent formulation will not be approved because of this decision.

Recent FDA decisions regarding generic opioids cloud the future of abuse-deterrent medications. In May, the FDA ruled that manufacturers will be allowed to bring to market as early as July 1 more generic forms of a non-abuse deterrent version of Opana ER. The FDA is also expected to decide soon whether to approve an application for a new, pure hydrocodone pill with no abuse-deterrent features.

CLAAD's executive director, Michael Barnes, explained the need for action: "The availability of more generic, non-abuse-deterrent opioids increases the supply of drugs that people are eager and able to abuse. The better approach is to replace that supply with abuse-deterrent medications."

The citizen petition is asking that the FDA act speedily in accordance with the urgency of the national prescription abuse epidemic. By law, the FDA has 180 days to reply.

About the Center for Lawful Access and Abuse Deterrence
The not-for-profit Center for Lawful Access and Abuse Deterrence (CLAAD) coordinates a comprehensive national effort to prevent the prescription drug fraud, diversion, misuse, and abuse while advancing patient access to high-quality medical care. CLAAD enables health professionals, law enforcement, businesses, and government, and others, to share resources and work together to improve public health and safety.  Follow @claad_coalition.


'/>"/>
SOURCE CLAAD
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CLAAD Warns of Increase in Prescription Drug Overdoses
2. CLAAD Names Eagle Advancement Institute as Honoree of Top 5 Technologies To Reduce Prescription Drug Abuse
3. CLAAD Highlights 5 Technologies To Reduce Prescription Drug Abuse
4. CLAAD Recognizes SMART/Script as Top 5 Technology To Reduce Rx Abuse
5. CLAAD Recognizes The Locking Cap as Top 5 Technology To Reduce Rx Abuse
6. CLAAD Selects Egalet As Top Five Technologies To Reduce Prescription Drug Abuse Honoree
7. Abuse Deterrent Medicines Developer Pisgah Laboratories, Inc. Wins Top 5 Technologies Award from CLAAD
8. TRICAST Debuts Part D Rejection Oversight Solution for Drug Plan Sponsors
9. Home Affairs Committees Drugs Report: Angelus Foundation Says the Prime Minister Should Not Have Rejected a Royal Commission
10. Express Scripts Recommends Rejection of TRC Capitals "Mini-Tender" Offer
11. New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... DIEGO , Dec. 9, 2016 aTyr Pharma, Inc. ... discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, ... at the upcoming BMO Prescriptions for Success Healthcare Conference at the ... on Wednesday, December 14, 2016, at 4:20 p.m. ET. ... ...
(Date:12/9/2016)... Department of Health Secretary Dr. Karen ... dispensaries under Act 16 are slated for publication in ... now available online . "The dispensary temporary ... operation; process for dispensing medical marijuana; security and surveillance ... dispensary facilities can be located," said Secretary Murphy. "Our ...
(Date:12/8/2016)... Dec. 8, 2016 IRIDEX Corporation (NASDAQ: ... issued shares of common stock, $0.01 par value (the "Offering" ... public offering.  The final terms of the Offering will depend ... and there can be no assurance as to whether or ... to use the net proceeds it will receive from this ...
Breaking Medicine Technology:
(Date:12/10/2016)... ... 10, 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) ... other healthcare organizations to promote diabetes education at the World Diabetes Day observance. ... of speakers from around the Commonwealth of Pennsylvania. Speakers included Dr. Renu ...
(Date:12/9/2016)... ... December 09, 2016 , ... The American ... audiologists—to remain a critical part of public access to hearing aid technology. , ... announced this week that, starting immediately, it would no longer enforce the ...
(Date:12/9/2016)... , ... December 09, 2016 , ... ... folded, pharmaceutical inserts and outserts. As a means of expanding capabilities Flottman ... will enable Flottman to individually code professional inserts (PIs) and patient package inserts ...
(Date:12/9/2016)... Woodland Hills, CA (PRWEB) , ... December 09, ... ... center for young adults, celebrated its 10th anniversary with the grand opening of ... Hills, California. The successful event spanned two days, December 2-3, and was attended ...
(Date:12/9/2016)... ... December 09, 2016 , ... The ... Hotel in New York, NY, on December 3rd, to benefit Holy Name Medical ... the annual event, which raised over $1 million - the largest event in ...
Breaking Medicine News(10 mins):